Financière de Tubize S.A.
TUB
株式のランク
#2119
Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a... Financière de Tubize SA, headquartered in Brussels, Belgium, operates as a global biopharmaceutical firm, primarily through its investment in UCB. The company is dedicated to discovering and advancing innovative medicines and solutions focused on neurological and immunological disorders. Its current commercial offerings include Cimzia, an established treatment for a range of inflammatory conditions such as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For partial-onset seizures in epilepsy, it provides Briviact, Vimpat, and Keppra, alongside Nayzilam, a nasal spray. Neupro addresses Parkinson's disease and restless legs syndrome. Additionally, the portfolio features Evenity, an injectable therapy for osteoporosis, and Bimzelx, used to manage moderate to severe plaque psoriasis. The company's development pipeline highlights several promising candidates: Staccato, aimed at stereotypical prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Other therapies under investigation include bimekizumab, which targets psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab, for conditions like myasthenia gravis, immune thrombocytopenia, myelin oligodendrocyte glycoprotein antibody disease, and autoimmune encephalitis; and dapirolizumab pegol, intended for systemic lupus erythematosus.
株価
$217.90
時価総額
$9.70B
変化（1日）
5.57%
変化（1年）
-20.53%
国
BE
取引 Financière de Tubize S.A. (TUB)
カテゴリー
Healthcare
Financière de Tubize S.A.（TUB）のEPS
June 2026 時点のEPS TTM: $2.62
Financière de Tubize S.A.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$2.62です。2023年末には、EPSは$2.19で、2022年のEPS$2.05と増加でした。
Financière de Tubize S.A.のEPS履歴（2003から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $2.62 | 24.83% |
| 2024 | $2.10 | -3.97% |
| 2023 | $2.19 | 6.83% |
| 2022 | $2.05 | -4.16% |
| 2021 | $2.14 | -69.99% |
| 2020 | $7.12 | -25,913.77% |
| 2019 | $-0.03 | -100.37% |
| 2018 | $7.37 | -4.38% |
| 2017 | $7.70 | 79.89% |
| 2016 | $4.28 | -17.32% |
| 2015 | $5.18 | 214.76% |
| 2014 | $1.65 | -13.29% |
| 2013 | $1.90 | -17.32% |
| 2012 | $2.30 | 22.27% |
| 2011 | $1.88 | 198.71% |
| 2010 | $0.63 | -88.03% |
| 2009 | $5.25 | -18,644.17% |
| 2008 | $-0.03 | -102.18% |
| 2007 | $1.30 | -90.76% |
| 2006 | $14.08 | 80.81% |
| 2005 | $7.79 | 111.12% |
| 2004 | $3.69 | -20.63% |
| 2003 | $4.65 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | 560.72% |
US
|
|
| $-7.98 | -404.42% |
US
|
|
| $-5.29 | -301.80% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 958.21% |
NL
|
